Palisade Bio announced new Phase 1a/b data for PALI-2108, an oral PDE4 inhibitor designed for targeted delivery to the colon and ileum in ulcerative colitis patients. The data show sustained active metabolite levels above the IC90 threshold, supporting once-daily dosing and localized drug activity in the colon, which reduces inflammation and fibrosis pathways. Clinical improvements were observed in biomarkers and histology, with 100% clinical response and 40% remission in patients. These results support advancing PALI-2108 into Phase 2 trials for ulcerative colitis and Crohn's disease.
Solaris Energy Infrastructure (SEI) maintains a Buy rating with a new price target of $97, driven by strong growth from its Power Solutions segment and a 2.2GW contracted capacity with major tech clients. Its upcoming inclusion in the S&P SmallCap 60...
XRP Ledger's AI agents have completed over 1 million transactions but with low financial volume, indicating the AI economy is still in early stages. Bitcoin mining veteran Chandler Guo predicts Bitcoin will hit $120,000 within a year and $500,000 in ...
Argan, Inc. reported a strong first quarter for fiscal year 2027 with a 50% increase in revenue, reaching a record $290.9 million. This growth was fueled by multiple project completions and a robust $2.8 billion backlog, supported by rising energy de...
The Global X Russell 2000 Covered Call ETF (RYLD) provides a high monthly yield of 11.9% and achieved a 20.5% total return over the past year. However, its strategy involving at-the-money options causes structural net asset value (NAV) erosion and ca...
A Cambridge study found Ethereum's annual energy consumption at 7.87 gigawatt-hours, making it the second-least energy-intensive proof-of-stake (PoS) blockchain when adjusted for market value. This marks a significant improvement from its previous pr...
